dm+d

Unassigned

New Medicines

Major depressive disorder with insomnia - adjunctive treatment

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

A small molecule selective orexin receptor type-2 antagonist, that reduces the activity of wakefulness-promoting neurons.
Annually, 5% of adults have an episode of depression. About one in four women and one in ten men will develop depression severe enough to require treatment at some time in their lives [1].
Major depressive disorder with insomnia - adjunctive treatment
Oral